Seasonal Affective Disorder (SAD) affects millions of Americans, and cases usually start to rise in late fall or early winter ...

de Filippis, R. and Al Foysal, A. (2024) Case Report: The Role of Monoamine Oxidase Inhibitors in Treating Resistant Depression. Open Access Library Journal, 11, 1-12. doi: 10.4236/oalib.1112369 .

'Functional unblinding was a major barrier to the approval of psychedelics as medicines to treat the patients who need them most,' said Dr. Andrew Chadeayne, CaaMTech CEO. 'I'm incredibly proud that ...

Mizuho reiterated its bullish stance on biotech Neumora Therapeutics Inc. on Wednesday, and predicted a positive outcome when the company reports data from a late-stage trial of its treatment for ...

People suffering from major depressive disorder (MDD) and treatment-resistant depression (TRD) often face challenging ...

Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revoluti ...

The criteria for diagnosing SAD are similar to diagnosing major ... depressive disorders. On average, SAD will last about ...

November 12, 2024) - MYND Life Sciences (CSE: MYND) (OTCQB: MYNDF) ("MYND" or the "Company") a clinical-stage life sciences company committed to the development and commercialization of a biomarker ...

We look forward to announcing topline data from KOASTAL-1, the first of three replicate studies in the pivotal Phase 3 KOASTAL program for the treatment of major depressive disorder (MDD), around the ...

AbbVie (ABBV) shares dropped 11% premarket as late-stage trials for schizophrenia drug emraclidine did not meet primary ...

Presentations include results from two pivotal studies (Studies 501 and 502) evaluating lumateperone as an adjunctive therapy to antidepressants ...

Transmagnetic stimulation (TMS) is an FDA-approved noninvasive neurostimulation intervention used to treat TRD. TMS delivers ...